Selenium exposure on breast cancer risk and progression: Comprehensive analysis identifies MSRB1 as a novel therapeutic target
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study reveals a protective link between selenium and breast cancer (BRCA) risk. A novel selenium-related risk score predicts patient outcomes and therapy response, identifying MSRB1 as a key therapeutic target.
Area Of Science
- Oncology
- Nutritional Biochemistry
- Genomics
Background
- Breast cancer (BRCA) is a leading global malignancy in women.
- Selenium (Se) influences BRCA patient survival, but its precise roles are not fully understood.
- The impact of Se on tumorigenesis, the tumor immune microenvironment (TIME), and precision therapy requires further investigation.
Purpose Of The Study
- To investigate the causal relationship between blood Se levels and BRCA risk using Mendelian randomization.
- To identify Se-related molecular patterns and develop a prognostic signature for BRCA patients.
- To explore potential therapeutic targets and drugs for BRCA treatment based on Se pathways.
Main Methods
- Mendelian randomization analysis to assess the causal effect of blood Se on BRCA risk.
- Transcriptome profiling and analysis of TCGA-BRCA and METABRIC cohorts to identify Se clusters and develop a Se-related risk score (SeRS).
- In vitro experiments to evaluate the functional role of MSRB1 in BRCA cells.
Main Results
- A protective causal link was established between blood Se and BRCA risk.
- Two distinct Se clusters (SeC1, SeC2) and a predictive SeRS incorporating SELENOH, GPX4, GPX1, MSRB1, TXRND1, and SELENOV were identified.
- MSRB1 was identified as a critical selenoprotein in BRCA, with its depletion inhibiting tumor progression and increasing oxidative stress; potential drugs were also identified.
Conclusions
- A novel selenoprotein-based classification and prognostic signature (SeRS) for BRCA patients were developed.
- The SeRS enhances personalized prognosis and guides precision therapy decisions.
- MSRB1 emerges as a promising therapeutic target for BRCA treatment, offering new insights into Se's role.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...